Zobrazeno 1 - 10
of 227
pro vyhledávání: '"du Bois, A"'
Autor:
Krämer P; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada., Talhouk A; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada., Brett MA; Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada., Chiu DS; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada.; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada., Cairns ES; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada., Scheunhage DA; Department of Pathology, Leiden University Medical Centre (LUMC), Leiden, the Netherlands., Hammond RFL; Barts Health National Health Service Trust, Department of Pathology, London, United Kingdom., Farnell D; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Nazeran TM; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Grube M; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany., Xia Z; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Senz J; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Leung S; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Feil L; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada., Pasternak J; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany., Dixon K; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada., Hartkopf A; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany., Krämer B; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany., Brucker S; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany., Heitz F; Kliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany.; Charité Campus Virchow-Klinikum, Department for Gynecology with the Center for Oncologic Surgery, Berlin, Germany., du Bois A; Kliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany., Harter P; Kliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany., Kommoss FKF; Heidelberg University Hospital, Institute of Pathology, Heidelberg, Germany., Sinn HP; Heidelberg University Hospital, Institute of Pathology, Heidelberg, Germany., Heublein S; Department of Obstetrics and Gynecology, Heidelberg University Hospital, Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany., Kommoss F; Medizin Campus Bodensee, Institute of Pathology, Friedrichshafen, Germany., Vollert HW; Department of Obstetrics and Gynecology, Medizin Campus Bodensee, Friedrichshafen, Germany., Manchanda R; Barts CRUK Cancer Centre, Wolfson Institute of Preventative Medicine, Queen Mary University of London, Charterhouse Square, London, United Kingdom.; Department of Gynaecological Oncology, St. Bartholomew's Hospital, London, United Kingdom., de Kroon CD; Department of Gynecology, Leiden University Medical Centre (LUMC), Leiden, the Netherlands., Nijman HW; Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., de Bruyn M; Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Thompson EF; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Bashashati A; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada.; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; School of Biomedical Engineering, University of British Columbia, Vancouver, British Columbia, Canada., McAlpine JN; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada., Singh N; Barts Health National Health Service Trust, Department of Pathology, London, United Kingdom., Tinker AV; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada.; Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada., Staebler A; University Hospital Tuebingen, Institute of Pathology and Neuropathology, Tuebingen, Germany., Bosse T; Department of Pathology, Leiden University Medical Centre (LUMC), Leiden, the Netherlands., Kommoss S; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany., Köbel M; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada., Anglesio MS; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada. m.anglesio@ubc.ca.; BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia's Gynecological Cancer Research Team (OVCARE), Vancouver, British Columbia, Canada.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Oct 15; Vol. 26 (20), pp. 5400-5410. Date of Electronic Publication: 2020 Jul 31.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer, Kati Erdmann, Susanne Füssel, Theresa Link, Andreas du Bois, Stefan Kommoss, Florian Heitz, Jalid Sehouli, Rainer Kimmig, Nikolaus de Gregorio, Barbara Schmalfeldt, Tjoung-Won Park-Simon, Klaus Baumann, Felix Hilpert, Marcel Grube, Willibald Schröder, Alexander Burges, Antje Belau, Lars Hanker, Jan Dominik Kuhlmann
Publikováno v:
Clinical Cancer Research. 28:4660-4668
Purpose: The identification of a robust IHC marker to predict the response to antiangiogenic bevacizumab in ovarian cancer is of high clinical interest. VEGF-A, the molecular target of bevacizumab, is expressed as multiple isoforms with pro- or antia
Autor:
Liina Salminen, Elena Ioana Braicu, Mitja Lääperi, Antti Jylhä, Sinikka Oksa, Sakari Hietanen, Jalid Sehouli, Hagen Kulbe, Andreas du Bois, Sven Mahner, Philipp Harter, Olli Carpén, Kaisa Huhtinen, Johanna Hynninen, Mika Hilvo
Publikováno v:
Cancers, Vol 13, Iss 8, p 1764 (2021)
Epithelial ovarian cancer (EOC) generally responds well to oncological treatments, but the eventual development of a refractory disease is a major clinical problem. Presently, there are no prognostic blood-based biomarkers for the stratification of E
Externí odkaz:
https://doaj.org/article/799ce520610648b6bb59a1ecacd93f86
Autor:
Enrico Vizza, Sonia Magni, Beyhan Ataseven, Vito Chiantera, Nicolò Bizzarri, Philipp Harter, Daniela Giuliani, Anna Fagotti, Debora Ferrari, Anna Myriam Perrone, Pierandrea De Iaco, Francesca De Felice, Jvan Casarin, Andreas du Bois, Robert Fruscio, Giacomo Corrado, Mareike Bommert, Giovanni Scambia, Stefano Cianci
Objective: The therapeutic role of pelvic and para-aortic lymphadenectomy in surgical staging of apparent early-stage epithelial ovarian cancer (eEOC) is still under debate. The aim of this study was to evaluate the potential therapeutic role of syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20118a1f853b9e3f6845eb7d6ef4fd46
http://hdl.handle.net/11585/810972
http://hdl.handle.net/11585/810972
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jalid Sehouli, Martina Gropp-Meier, Behnaz Aminossadati, Nikolaus de Gregorio, Alexander Burges, Ulrich Canzler, Ahmed El-Balat, Barbara Schmalfeldt, Annette Hasenburg, Pauline Wimberger, Christian Jackisch, Uwe Wagner, Philipp Harter, Petra Neuser, Hans-Joachim Lück, Andreas du Bois, Werner Meier, Sven Mahner, Jacobus Pfisterer, Stefan Kommoss
Publikováno v:
Archives of Gynecology and Obstetrics. 301:1267-1274
Although thrombocytosis in patients with primary ovarian cancer has been widely investigated, there are only very few data about the role of thrombocytosis in recurrent ovarian cancer. The aim of our study was to investigate the impact of pretreatmen
Publikováno v:
Journal of Clinical Oncology. 37:2398-2405
Autor:
Christina Fotopoulou, Andrea Rockall, Haonan Lu, Philippa Lee, Giacomo Avesani, Luca Russo, Federica Petta, Beyhan Ataseven, Kai-Uwe Waltering, Jens Albrecht Koch, William R. Crum, Paula Cunnea, Florian Heitz, Philipp Harter, Eric O. Aboagye, Andreas du Bois, Sonia Prader
Publikováno v:
British journal of cancer. 126(7)
Background Predictive models based on radiomics features are novel, highly promising approaches for gynaecological oncology. Here, we wish to assess the prognostic value of the newly discovered Radiomic Prognostic Vector (RPV) in an independent cohor
Autor:
Olli Carpén, Andreas du Bois, Elena Ioana Braicu, Hagen Kulbe, Johanna Hynninen, Philipp Harter, Mika Hilvo, Jalid Sehouli, Antti Jylhä, Sinikka Oksa, Mitja Lääperi, Sven Mahner, Sakari Hietanen, Kaisa Huhtinen, Liina Salminen
Publikováno v:
Cancers
Volume 13
Issue 8
Salminen, L, Braicu, E I, Lääperi, M, Jylhä, A, Oksa, S, Hietanen, S, Sehouli, J, Kulbe, H, Bois, A D, Mahner, S, Harter, P, Carpén, O, Huhtinen, K, Hynninen, J & Hilvo, M 2021, ' A novel two-lipid signature is a strong and independent prognostic factor in ovarian cancer ', Cancers, vol. 13, no. 8, 1764 . https://doi.org/10.3390/cancers13081764
Cancers, Vol 13, Iss 1764, p 1764 (2021)
Volume 13
Issue 8
Salminen, L, Braicu, E I, Lääperi, M, Jylhä, A, Oksa, S, Hietanen, S, Sehouli, J, Kulbe, H, Bois, A D, Mahner, S, Harter, P, Carpén, O, Huhtinen, K, Hynninen, J & Hilvo, M 2021, ' A novel two-lipid signature is a strong and independent prognostic factor in ovarian cancer ', Cancers, vol. 13, no. 8, 1764 . https://doi.org/10.3390/cancers13081764
Cancers, Vol 13, Iss 1764, p 1764 (2021)
Simple Summary Most ovarian cancer patients initially show a response to primary treatments, but the development of refractory disease is a major problem. Currently, there are no blood-based prognostic biomarkers, and the prognosis of a patient is de